Targets & Mechanisms: IL-17 inhibitors: good news, bad news 

 

Table 1. Opportunities and obstacles for IL-17 inhibitors. Studies by two independent teams suggest inhibitors of IL-17A signaling could help treat cancers that are resistant to VEGF inhibitors but could also destabilize atherosclerotic plaques and thus increase the risk of cardiovascular events. The findings therefore present a repurposing opportunity and a safety caveat to companies developing inhibitors of members of the
IL-17 family or IL-17 receptor (IL17R; IL17RA) to treat autoimmune and inflammatory indications.
Source: BCIQ: BioCentury Online Intelligence

Company

Compound

Target(s)a

Type

Status

Amgen Inc. (NASDAQ:AMGN)/AstraZeneca plc (LSE:AZN; NYSE:AZN)

Brodalumab (AMG 827)

IL17R

Antibody

Phase III to treat psoriasis;
Phase II to treat psoriatic arthritis and asthma

Eli Lilly and Co. (NYSE:LLY)

Ixekizumab (LY2439821)

IL-17A

Antibody

Phase III to treat psoriasis and psoriatic arthritis; Phase II to treat rheumatoid arthritis (RA)

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151)

KHK4827

IL17R

Antibody

Phase III to treat psoriasis

Novartis AG (NYSE:NVS; SIX:NOVN)

Secukinumab (AIN457)

IL-17A

Antibody

Phase III to treat ankylosing spondylitis, psoriasis, psoriatic arthritis and RA; Phase II to treat multiple sclerosis

4SC AG (Xetra:VSC)

Vidofludimus (4SC-101)

IL-17 expression and dihydroorotate dehydrogenase (DHODH)

Small molecule

Phase II to treat inflammatory bowel disease

NovImmune S.A./Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY)

NI-1401 (RG7624; MCAF5352A)

IL-17A and IL-17F

Antibody

Phase I to treat autoimmune diseases

AnaptysBio Inc.

ANB004

IL-17

Antibody

Preclinical to treat autoimmune and inflammatory diseases

Covagen AG

COVA322

IL-17A and tumor necrosis factor (TNF)

Protein

Preclinical to treat inflammatory diseases

Ensemble Therapeutics Corp./Novartis AG

E-036041

IL-17A

Macrocycle

Preclinical to treat arthritis

Pieris AG

PRS-190

IL-17 and IL-23

Protein

Preclinical to treat autoimmune diseases

aUnless noted, the specific form of IL-17 (A, B, C, D E and/or F) inhibited by the compound is undisclosed.